Avidity Biosciences to Participate in Upcoming Investor Conference
Avidity Biosciences (Nasdaq: RNA), a developer of Antibody Oligonucleotide Conjugates (AOCs™), has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference. The company's management will engage in a fireside chat scheduled for Tuesday, April 8, 2025, at 3:00 p.m. ET.
Investors and interested parties can access the live webcast and replay of the presentation through the 'Events and Presentations' section on Avidity's investor relations website at aviditybiosciences.investorroom.com/events-and-presentations.
Avidity Biosciences (Nasdaq: RNA), un sviluppatore di Coniugati di Oligonucleotidi Anticorpali (AOCs™), ha annunciato la sua partecipazione alla prossima 24ª Conferenza Virtuale Annuale sulla Salute di Needham. La direzione dell'azienda parteciperà a una chiacchierata informale programmata per martedì 8 aprile 2025, alle 15:00 ET.
Gli investitori e le parti interessate possono accedere alla diretta e alla registrazione della presentazione attraverso la sezione 'Eventi e Presentazioni' sul sito web delle relazioni con gli investitori di Avidity all'indirizzo aviditybiosciences.investorroom.com/events-and-presentations.
Avidity Biosciences (Nasdaq: RNA), un desarrollador de Conjugados de Oligonucleótidos Anticuerpos (AOCs™), ha anunciado su participación en la próxima 24ª Conferencia Virtual Anual de Salud de Needham. La dirección de la empresa participará en una charla informal programada para martes, 8 de abril de 2025, a las 3:00 p.m. ET.
Los inversores y las partes interesadas pueden acceder a la transmisión en vivo y a la repetición de la presentación a través de la sección 'Eventos y Presentaciones' en el sitio web de relaciones con inversores de Avidity en aviditybiosciences.investorroom.com/events-and-presentations.
Avidity Biosciences (Nasdaq: RNA)는 항체 올리고뉴클레오타이드 접합체(AOCs™) 개발업체로서 다가오는 제24회 니드햄 연례 가상 의료 컨퍼런스에 참여할 것이라고 발표했습니다. 회사의 경영진은 2025년 4월 8일 화요일 오후 3시 ET에 예정된 화상 대화에 참여할 것입니다.
투자자 및 관심 있는 당사자는 Avidity의 투자자 관계 웹사이트의 '이벤트 및 발표' 섹션을 통해 발표의 라이브 웹캐스트 및 재생을 이용할 수 있습니다: aviditybiosciences.investorroom.com/events-and-presentations.
Avidity Biosciences (Nasdaq: RNA), un développeur de Conjugués d'Oligonucléotides Anticorps (AOCs™), a annoncé sa participation à la prochaine 24e Conférence Virtuelle Annuelle sur la Santé de Needham. La direction de l'entreprise participera à une discussion informelle prévue pour mardi 8 avril 2025, à 15h00 ET.
Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct et à la rediffusion de la présentation via la section 'Événements et Présentations' sur le site web des relations investisseurs d'Avidity à l'adresse aviditybiosciences.investorroom.com/events-and-presentations.
Avidity Biosciences (Nasdaq: RNA), ein Entwickler von Antikörper-Oligonukleotid-Konjugaten (AOCs™), hat seine Teilnahme an der bevorstehenden 24. jährlichen virtuellen Gesundheitskonferenz von Needham angekündigt. Das Management des Unternehmens wird an einem informellen Gespräch teilnehmen, das für Dienstag, den 8. April 2025, um 15:00 Uhr ET angesetzt ist.
Investoren und interessierte Parteien können die Live-Übertragung und die Wiederholung der Präsentation über den Bereich 'Veranstaltungen und Präsentationen' auf der Investor-Relations-Website von Avidity unter aviditybiosciences.investorroom.com/events-and-presentations abrufen.
- None.
- None.
- 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 3:00 p.m. ET
Live webcast of the event, up-to-date event details and an archived replay will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare neuromuscular diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in
Investor Contact:
Kat Lange
(619) 837-5014
investors@aviditybio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conference-302416463.html
SOURCE Avidity Biosciences, Inc.
FAQ
When is Avidity Biosciences (RNA) presenting at the Needham Healthcare Conference 2025?
How can investors watch Avidity Biosciences' (RNA) Needham Conference presentation?
What type of presentation will Avidity Biosciences (RNA) give at the Needham Conference?
What is Avidity Biosciences' (RNA) main therapeutic focus?
